News C


ertara, a provider of decision support technology and consulting services specialising in drug development and healthcare, has


announced that it has established two ‘Phoenix Centers of Excellence’ in Asia. Te two new centres are located at the Peking Union Medical College (PUMC) Hospital in Beijing, China, and Keio University in Tokyo, Japan. Phoenix soſtware is used for


pharmacokinetic (PK), pharmacodynamic (PD), and toxicokinetic (TK) modelling and simulation. ‘As regulators and sponsors recognise


the growing importance of model-based drug development (MBDD), Certara has committed to educating the next generation of experts in this field, on a global basis,’ said Certara chief executive officer Dr Edmundo Muniz. ‘We are achieving that goal by partnering with eminent scientists at designated academic centres of excellence around the world and providing them with access to our Phoenix soſtware – which is the gold standard in PK/PD – for teaching and research.’ Te Phoenix Centers of Excellence act as


a hub for developing knowledge around the Phoenix soſtware, and routinely publish their


For regular news updates, please visit www.scientific-computing.com/news


Certara establishes ‘Phoenix PK/ PD Centers of Excellence’ in Asia


technology for first-in-human, point-of-care, and late-phase clinical trials. Founded by the Rockefeller Foundation in 1921, PUMC Hospital conducts clinical research into severe, rare and complicated diseases. It has 4,000 employees and is affiliated with both PUMC and the Chinese Academy of Medical Sciences. For the past six years, PUMC Hospital has been named the Number 1 hospital in the List of the Best Chinese Hospitals published by FuDan University, the most famous ranking list in China. For the collaboration in Japan, Certara


Keio University, Tokyo


work so that other researchers can benefit from their progress. Tey also serve as an informal scientific advisory group. At PUMC Hospital, Professor Pei Hu,


MD, professor, and director of its Clinical Pharmacology Research Center, will use Certara’s modelling and simulation


IBM AND SIEMENS HEALTHINEERS JOIN FORCES


IBM has joined forces with Siemens Healthineers in a five-year deal aimed at helping healthcare organisations to provide better-value care to patients. The two companies have forged strategic alliances before, but never in the healthcare arena.


The companies say they want to help health professionals ‘navigate unprecedented changes propelled by a growing volume and diversity of health data, an ageing global


population, increasing prevalence of chronic diseases, changes in healthcare payment models, and the digitisation and consumerisation of healthcare’.


Matthias Platsch, head of services at Siemens Healthineers, explained: ‘Combining our strengths, Siemens Healthineers and IBM can effectively help providers transition to a value-based healthcare environment. We will bring the power of Siemens Healthineers’ extensive


22 SCIENTIFIC COMPUTING WORLD


relationships with providers and our deep domain expertise in clinical workflows, services, and digital health technologies to bear to help bring population health management offerings to healthcare providers. ‘The new alliance fits perfectly into the services business of Siemens Healthineers. Thus we will enter the rapidly-growing PHM market which is expected to play a significant role in end-to-end value-based healthcare.’ Deborah DiSanzo, general


manager for IBM Watson Health, added: ‘We are at an unprecedented time in healthcare. Mature and developing markets are increasingly focused on how patient outcomes are optimised, quality is standardised among individuals and across populations, and costs are reduced. Siemens and IBM are ideal partners to work at the forefront of this evolution and enable personalised healthcare in the US and globally.’


@scwmagazine l www.scientific-computing.com


selected to further develop their ongoing relationship with Keio University, the oldest institute of higher education in Japan. At Keio University, Yusuke Tanigawara, Professor of Clinical Pharmacokinetics and Pharmacodynamics at Keio University School of Medicine will run the centre. Phoenix soſtware is used by 6,000


researchers at 1,500 biopharmaceutical companies and 200 academic institutions in 60 countries. Phoenix is employed by many global regulatory agencies including the United States Food and Drug Administration, the Japanese Pharmaceuticals and Medical Devices Agency, and China Food and Drug Administration.


GDFL


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36